Publications by authors named "Hashim Mann"

Claim this Profile
S
Safety and efficacy of BCMA-directed chimeric antigen receptor T-cell therapy for the treatment of plasma cell leukemia.
Gliceida M Galarza Fortuna, Lauren Peres, Elena Nazarenko, Andre De Menezes Silva Corraes, Vanna N Hovanky, Hashim Mann

Blood Adv· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma.
Surbhi Sidana, Krina K Patel, Lauren C Peres, Radhika Bansal, Mehmet H Kocoglu, Hashim Mann

Blood· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined MEK1/2 and ATR inhibition promotes myeloma cell death through a STAT3-dependent mechanism in vitro and in vivo.
Lin Li, Xiaoyan Hu, Jewel Nkwocha, Maciej Kmieciak, Mark B Meads, Hashim Mann

Br J Haematol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-canonical role for the ataxia-telangiectasia-Rad3 pathway in STAT3 activation in human multiple myeloma cells.
Lin Li, Xiaoyan Hu, Jewel Nkwocha, Kanika Sharma, Maciej Kmieciak, Hashim Mann

Cell Oncol (Dordr)· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Belantamab mafodotin in patients with relapsed/refractory AL amyloidosis with myeloma.
Yifei Zhang, Amandeep Godara, Stacey Pan, Denis Toskic, Hashim Mann

Ann Hematol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating the Therapeutic Potential of Idecabtagene Vicleucel in the Treatment of Multiple Myeloma: Evidence to Date.
Hashim Mann, Raymond L Comenzo

Onco Targets Ther· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Smoldering multiple myeloma - Past, present, and future.
Hashim Mann, Vatsala Katiyar, Cindy Varga, Raymond L Comenzo

Blood Rev· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rapid and sustained decline in CXCL-10 (IP-10) annotates clinical outcomes following TNF-α antagonist therapy in hospitalized patients with severe and critical COVID-19 respiratory failure.
Hilal Hachem, Amandeep Godara, Courtney Schroeder, Daniel Fein, Hashim Mann

medRxiv· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rapid and sustained decline in CXCL-10 (IP-10) annotates clinical outcomes following TNFα-antagonist therapy in hospitalized patients with severe and critical COVID-19 respiratory failure.
Hilal Hachem, Amandeep Godara, Courtney Schroeder, Daniel Fein, Hashim Mann

J Clin Transl Sci· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factors associated with bleeding events in patients on rivaroxaban for non-valvular atrial fibrillation: A real-world experience.
Tauseef Akhtar, Juan Del Cid Fratti, Jishanth Mattumpuram, Setri Fugar, Alok Uprety, Hashim Mann

Int J Cardiol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis